{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:12:39Z","timestamp":1789517559097,"version":"build-2803163510"},"reference-count":34,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.11590","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T11:00:43Z","timestamp":1568804443000},"page":"e1911590","source":"Crossref","is-referenced-by-count":18,"title":["Comparison of Prescribing Patterns Before and After Implementation of a National Policy to Reduce Inappropriate Alprazolam Prescribing in Australia"],"prefix":"10.1001","volume":"2","author":[{"given":"Andrea L.","family":"Schaffer","sequence":"first","affiliation":[{"name":"Centre for Big Data Research in Health, University of New South Wales Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Buckley","sequence":"additional","affiliation":[{"name":"School of Medical Sciences, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Cairns","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Sydney, Sydney, Australia"},{"name":"New South Wales Poisons Information Centre, The Children\u2019s Hospital at Westmead, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie","family":"Pearson","sequence":"additional","affiliation":[{"name":"Centre for Big Data Research in Health, University of New South Wales Sydney, Sydney, Australia"},{"name":"Menzies Centre for Health Policy, University of Sydney, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"issue":"2","key":"zoi190451r1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2190\/8FR4-QYY1-7MYG-2AGJ","article-title":"A controlled study of the effects of state surveillance on indicators of problematic and non-problematic benzodiazepine use in a Medicaid population.","volume":"34","author":"Ross-Degnan","year":"2004","journal-title":"Int J Psychiatry Med"},{"issue":"2","key":"zoi190451r2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/09595230701829413","article-title":"The effects of the market withdrawal of temazepam gel capsules on benzodiazepine injecting in Sydney, Australia.","volume":"27","author":"Degenhardt","year":"2008","journal-title":"Drug Alcohol Rev"},{"issue":"2","key":"zoi190451r3","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/S0149-2918(04)90030-6","article-title":"A retrospective data analysis of the impact of the New York triplicate prescription program on benzodiazepine use in Medicaid patients with chronic psychiatric and neurologic disorders.","volume":"26","author":"Simoni-Wastila","year":"2004","journal-title":"Clin Ther"},{"issue":"1","key":"zoi190451r4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1370\/afm.1319","article-title":"Reimbursement restriction and moderate decrease in benzodiazepine use in general practice.","volume":"10","author":"Hoebert","year":"2012","journal-title":"Ann Fam Med"},{"issue":"4","key":"zoi190451r5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/pds.v27.4","article-title":"The impact of permissive and restrictive pharmaceutical policies on quetiapine dispensing: evaluating a policy pendulum using interrupted time series analysis.","volume":"27","author":"Brett","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"zoi190451r6","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.v28.5","article-title":"Impact of delisting high-strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada.","volume":"28","author":"Martins","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi190451r7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1377\/hlthaff.23.1.135","article-title":"Benefits and risks of increasing restrictions on access to costly drugs in Medicaid.","volume":"23","author":"Soumerai","year":"2004","journal-title":"Health Aff (Millwood)"},{"issue":"6","key":"zoi190451r8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1001\/jama.1990.03440060077036","article-title":"Withdrawing payment for nonscientific drug therapy: intended and unexpected effects of a large-scale natural experiment.","volume":"263","author":"Soumerai","year":"1990","journal-title":"JAMA"},{"issue":"5","key":"zoi190451r9","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1097\/MLR.0000000000000897","article-title":"Counter-point: staying honest when policy changes backfire.","volume":"56","author":"Lu","year":"2018","journal-title":"Med Care"},{"issue":"9","key":"zoi190451r10","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/pds.3480","article-title":"A critical review of methods to evaluate the impact of FDA regulatory actions.","volume":"22","author":"Briesacher","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi190451r11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/jcp.2012.37.issue-1","article-title":"The intended and unintended consequences of benzodiazepine monitoring programmes: a review of the literature.","volume":"37","author":"Fisher","year":"2012","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"zoi190451r12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1001\/archinte.166.5.572","article-title":"Racial disparities in access after regulatory surveillance of benzodiazepines.","volume":"166","author":"Pearson","year":"2006","journal-title":"Arch Intern Med"},{"key":"zoi190451r13","doi-asserted-by":"publisher","first-page":"j760","DOI":"10.1136\/bmj.j760","article-title":"Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis.","volume":"356","author":"Sun","year":"2017","journal-title":"BMJ"},{"key":"zoi190451r14","doi-asserted-by":"publisher","first-page":"h2698","DOI":"10.1136\/bmj.h2698","article-title":"Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study.","volume":"350","author":"Park","year":"2015","journal-title":"BMJ"},{"issue":"4","key":"zoi190451r15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.amepre.2015.03.040","article-title":"Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines.","volume":"49","author":"Jones","year":"2015","journal-title":"Am J Prev Med"},{"issue":"1","key":"zoi190451r16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bcp.2004.58.issue-1","article-title":"Alprazolam is relatively more toxic than other benzodiazepines in overdose.","volume":"58","author":"Isbister","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"zoi190451r17","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/JCP.0b013e31822d0012","article-title":"The efficacy and safety of alprazolam versus other benzodiazepines in the treatment of panic disorder.","volume":"31","author":"Moylan","year":"2011","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"zoi190451r18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/dar.2012.31.issue-4","article-title":"The use of alprazolam by people who inject drugs in Melbourne, Australia.","volume":"31","author":"Horyniak","year":"2012","journal-title":"Drug Alcohol Rev"},{"issue":"3","key":"zoi190451r19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1753-6405.2010.00533.x","article-title":"The contribution of injecting drug users in Sydney, Melbourne and Brisbane to rising benzodiazepine use in Australia 2000 to 2006.","volume":"34","author":"Smith","year":"2010","journal-title":"Aust N Z J Public Health"},{"key":"zoi190451r20","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1111\/j.1521-0391.2012.00298.x","article-title":"Characteristics of alprazolam-related deaths compiled by a centralized state medical examiner.","volume":"21","author":"Shah","year":"2012","journal-title":"Am J Addict"},{"issue":"4","key":"zoi190451r21","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5694\/mja12.10986","article-title":"Recent increase in detection of alprazolam in Victorian heroin-related deaths.","volume":"198","author":"Rintoul","year":"2013","journal-title":"Med J Aust"},{"issue":"1","key":"zoi190451r22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0897190013515001","article-title":"Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics.","volume":"27","author":"Jann","year":"2014","journal-title":"J Pharm Pract"},{"issue":"4","key":"zoi190451r25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5694\/mja13.10982","article-title":"Clenbuterol toxicity: a NSW poisons information centre experience.","volume":"200","author":"Brett","year":"2014","journal-title":"Med J Aust"},{"issue":"8","key":"zoi190451r26","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jamainternmed.2016.2992","article-title":"Interrupted time series analysis of the effect of rescheduling alprazolam in Australia: taking control of prescription drug use.","volume":"176","author":"Schaffer","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"12","key":"zoi190451r29","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1001\/jamasurg.2018.2651","article-title":"Association of hydrocodone schedule change with opioid prescriptions following surgery.","volume":"153","author":"Habbouche","year":"2018","journal-title":"JAMA Surg"},{"issue":"10","key":"zoi190451r30","doi-asserted-by":"publisher","first-page":"696","DOI":"10.5694\/mja12.11331","article-title":"The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids.","volume":"199","author":"Nielsen","year":"2013","journal-title":"Med J Aust"},{"issue":"5","key":"zoi190451r31","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5694\/j.1326-5377.2003.tb05162.x","article-title":"Doctors\u2019 perceptions and attitudes to prescribing within the Authority Prescribing System.","volume":"178","author":"Liaw","year":"2003","journal-title":"Med J Aust"},{"issue":"5","key":"zoi190451r32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.18773\/austprescr.2015.055","article-title":"Management of benzodiazepine misuse and dependence.","volume":"38","author":"Brett","year":"2015","journal-title":"Aust Prescr"},{"issue":"12","key":"zoi190451r33","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/add.2011.106.issue-12","article-title":"Benzodiazepines revisited: will we ever learn?","volume":"106","author":"Lader","year":"2011","journal-title":"Addiction"},{"key":"zoi190451r23","unstructured":"NPS MedicineWise. Reduced pack sizes and delisting of 2 mg doses of alprazolam (Alprax, GenRx Alprazolam, Kalma) for panic disorder. https:\/\/www.nps.org.au\/radar\/articles\/reduced-pack-sizes-and-delisting-of-2-mg-doses-of-alprazolam-alprax-gen-rx-alprazolam-kalma-for-panic-disorder. Accessed February 27, 2019."},{"key":"zoi190451r24","unstructured":"Australian Government Department of Health. Pharmaceutical Benefits Scheme: alprazolam. http:\/\/www.pbs.gov.au\/medicine\/item\/11186R-11187T-11205R. Accessed April 1, 2019."},{"key":"zoi190451r27","unstructured":"World Health Organization. ATC\/DD Index 2019. https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed August 8, 2019."},{"key":"zoi190451r28","unstructured":"Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice - part B: benzodiazepines. https:\/\/www.racgp.org.au\/clinical-resources\/clinical-guidelines\/key-racgp-guidelines\/view-all-racgp-guidelines\/prescribing-drugs-of-dependence\/prescribing-drugs-of-dependence-part-b. Accessed April 1, 2019."},{"key":"zoi190451r34","unstructured":"Pharmaceutical Benefits Scheme Drug Utilisation Sub Committee. Alprazolam: review of PBS utilisation following rescheduling to Schedule 8. http:\/\/www.pbs.gov.au\/info\/industry\/listing\/participants\/public-release-docs\/2015-10\/alprazolam-dusc-prd-2015-10-abstract. Accessed July 19, 2019."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2751394\/schaffer_2019_oi_190451.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T20:03:31Z","timestamp":1664395411000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2751394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11590","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,18]]}}}